Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study.

Autor: Zattera L; Department of Anesthesiology and Critical Care, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain - luigizattera@gmail.com.; Department of Intensive Care, Erasme Hospital, Free University of Brussels, Brussels, Belgium - luigizattera@gmail.com., Veliziotis I; Department of Intensive Care, Erasme Hospital, Free University of Brussels, Brussels, Belgium., Benitez-Cano A; Department of Anesthesiology and Critical Care, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain., Ramos I; Department of Anesthesiology and Critical Care, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain., Larrañaga L; Department of Anesthesiology and Critical Care, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain., Nuñez M; Department of Anesthesiology and Critical Care, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain., Román L; Department of Anesthesiology and Critical Care, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain., Adalid I; Department of Anesthesiology and Critical Care, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain., Ferrando C; Department of Anesthesiology and Critical Care, Hospital Clinic, Barcelona, Spain.; August Pi i Sunyer Research Institute, Barcelona, Spain., Muñoz G; Department of Anesthesiology and Critical Care, Hospital Clinic, Barcelona, Spain., Arruti E; Ubikare Technology, Vizcaya, Spain., Minini A; Department of Intensive Care, Erasme Hospital, Free University of Brussels, Brussels, Belgium., Bassas E; Department of Anesthesiology and Critical Care, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain., Hernández M; Department of Anesthesiology and Critical Care, Hospital Universitario Cruces, Barakaldo, Spain., Taccone FS; Department of Intensive Care, Erasme Hospital, Free University of Brussels, Brussels, Belgium., Peluso L; Department of Intensive Care, Erasme Hospital, Free University of Brussels, Brussels, Belgium., Adalia R; Department of Anesthesiology and Critical Care, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Minerva anestesiologica [Minerva Anestesiol] 2022 Apr; Vol. 88 (4), pp. 259-271. Date of Electronic Publication: 2022 Jan 24.
DOI: 10.23736/S0375-9393.22.15942-0
Abstrakt: Background: High levels of procalcitonin (PCT) have been associated with a higher risk of mortality in COVID-19 patients. We explored the prognostic role of early PCT assessment in critically ill COVID-19 patients and whether PCT predictive performance would be influenced by immunosuppression.
Methods: Retrospective multicentric analysis of prospective collected data in COVID-19 patients consecutively admitted to 36 intensive care units (ICUs) in Spain and Andorra from March to June 2020. Adult (>18 years) patients with confirmed COVID-19 and available PCT values (<72 hours from ICU admission) were included. Patients were considered as "no immunosuppression" (NI), "chronic immunosuppression" (CI) and "acute immunosuppression" (AIT if only tocilizumab; AIS if only steroids, AITS if both). The primary outcome was the ability of PCT to predict ICU mortality.
Results: Of the 1079 eligible patients, 777 patients were included in the analysis. Mortality occurred in 227 (28%) patients. In the NI group 144 (19%) patients were included, 67 (9%) in the CI group, 66 (8%) in the AIT group, 262 (34%) in the AIS group and 238 (31%) in the AITS group; PCT was significantly higher in non-survivors when compared with survivors (0.64 [0.17-1.44] vs. 0.23 [0.11-0.60] ng/mL; P<0.01); however, in the multivariable analysis, PCT values was not independently associated with ICU mortality. PCT values and ICU mortality were significantly higher in patients in the NI and CI groups.
Conclusions: PCT values are not independent predictors of ICU mortality in COVID-19 patients. Acute immunosuppression significantly reduced PCT values, although not influencing its predictive value.
Databáze: MEDLINE